Citation Report
List of articles citing

Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding

DOI: 10.1155/2018/3293584
BioMed Research International, 2018, 2018, 3293584.

#	Paper	IF	Citations
22	From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators. *Biological Chemistry*, **2018**, 399, 679-690	4.5	36
21	CB2-deficiency is associated with a stronger hypertrophy and remodeling of the right ventricle in a murine model of left pulmonary artery occlusion. *Life Sciences*, **2018**, 215, 96-105	6.8	6
20	Response to: Comment on "Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding". *BioMed Research International*, **2018**, 2018, 7491284	3	
19	Comment on "Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding". *BioMed Research International*, **2018**, 2018, 6593682	3	1
18	Effects of Riociguat on Right Ventricular Remodelling in Chronic Thromboembolic Pulmonary Hypertension Patients: A Prospective Study. *Canadian Journal of Cardiology*, **2018**, 34, 1137-1144	3.8	5
17	Discovery and development of sGC stimulators for the treatment of pulmonary hypertension and rare diseases. *Nitric Oxide - Biology and Chemistry*, **2018**, 77, 88-95	5	22
16	Emerging therapies for right ventricular dysfunction and failure. *Cardiovascular Diagnosis and Therapy*, **2020**, 10, 1735-1767	2.6	5
15	Animal models of right heart failure. *Cardiovascular Diagnosis and Therapy*, **2020**, 10, 1561-1579	2.6	4
14	Clinical Significance of Guanylate Cyclase Stimulator, Riociguat, on Right Ventricular Functional Improvement in Patients with Pulmonary Hypertension. *Cardiology*, **2021**, 146, 130-136	1.6	3
13	Right heart failure in pulmonary hypertension: Diagnosis and new perspectives on vascular and direct right ventricular treatment. *British Journal of Pharmacology*, **2021**, 178, 90-107	8.6	17
12	The effect of selected drugs on the mitigation of myocardial injury caused by gamma radiation. *Canadian Journal of Physiology and Pharmacology*, **2021**, 99, 80-88	2.4	0
11	LncRNA HOXA-AS3 Promotes the Progression of Pulmonary Arterial Hypertension through Mediation of miR-675-3p/PDE5A Axis. *Biochemical Genetics*, **2021**, 59, 1158-1172	2.4	2
10	Exploring Functional Differences between the Right and Left Ventricles to Better Understand Right Ventricular Dysfunction. *Oxidative Medicine and Cellular Longevity*, **2021**, 2021, 9993060	6.7	1
9	Systemic Sclerosis and Systemic Lupus Erythematosus Overlap Syndrome with Pulmonary Arterial Hypertension Successfully Treated with Immunosuppressive Therapy and Riociguat. *Cureus*, **2019**, 11, e4327	1.2	6
8	Potential biomarkers and therapeutic targets of idiopathic pulmonary arterial hypertension.. *Physiological Reports*, **2022**, 10, e15101	2.6	1
7	At the Intersection of Cardiology and Oncology: TGF□s as a Clinically Translatable Therapy for TNBC Treatment and as a Major Regulator of Post-Chemotherapy Cardiomyopathy.. *Cancers*, **2022**, 14,	6.6	
6	Riociguat attenuates left ventricular proteome and microRNA profile changes after experimental aortic stenosis in mice. *British Journal of Pharmacology*,	8.6	1

5	The thromboxane receptor antagonist NTP42 promotes beneficial adaptation and preserves cardiac function in experimental models of right heart overload. 9,	0
4	Soluble guanylate cyclase stimulator riociguat in the palette of modern specific therapy for precapillary pulmonary hypertension: from the pathophysiological basis to the results of current research. **2023**, 19, 45-52	0
3	A review on experimental surgical models and anesthetic protocols of heart failure in rats. 10,	0
2	Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model. 14,	0
1	Advances in the discovery of drugs that treat pulmonary arterial hypertension. **2023**, 18, 445-466	0